Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: Webinars

Webinar presented by Integral Molecular and Fierce Biotech – Mobilizing Safe Research Tools for Pandemic Preparedness

Thursday, October 12, 2023
8 am PT, 11 am ET, 17:00 CET
Register now

A fundamental research question resonates in the face of growing pandemic threats: How can we proactively develop countermeasures against future viral outbreaks? A critical component of future responses will be innovative research tools, including pseudoviruses that enable the safe study of highly pathogenic viruses in BSL-2 facilities. In this webinar, leaders in industry and academia discuss their experiences using such tools to study and develop therapeutics against influenza, SARS-CoV-2, and dengue viruses.

Topics include:

  • Using pseudovirus Reporter Virus Particles (RVPs) in place of live viruses, featuring their utility for neutralization assays and determining antibody titers
  • The flexibility of RVPs, and the ease of generating modified versions that allow the safe study of new virus variants and mutations of interest
  • Case studies illustrating the use of innovative research tools—including pseudoviruses and epitope mapping—in developing vaccines and treatments for a range of viral pathogens


Fierce and Integral Molecular Webinar- Mobilizing Safe Research Tools for Pandemic Preparedness. Headshots of webinar speakers: Kyle Doolan, Ph.D. of Integral Molecular, Chun-Nan Chen, Ph.D. of Single Cell Technology, Inc. and James E. Crowe, Jr., M.D. of Vanderbilt University Medical Center.

Register now

Webinar presented by Integral Molecular and Fierce Biotech – Conquering Undruggable Targets to Obtain Preclinical Antibodies

Thursday, September 14, 2023
8 am PT, 11 am ET, 17:00 CET
Register now

Despite the remarkable growth of antibody-based therapies in recent years, numerous promising targets remain untapped. Many targets have resisted conventional discovery approaches because they are highly conserved, structurally complex, or they present other technical hurdles. In this webinar, industry experts will share innovative strategies they have used to unlock challenging targets including membrane proteins.

They will discuss:

  • Key questions that scientists should ask before embarking on an antibody discovery campaign
  • How to leverage advancements in immunization—including RNA—to target native epitopes and generate diverse antibodies
  • Strategies for unlocking conserved antibody targets using approaches such as divergent host species
  • Case studies of two challenging targets, claudin 6 and GPRC5D, with a focus on key innovations that led to the discovery of preclinical candidates including CTIM-76, a pre-IND (Investigational New Drug) stage molecule being developed for oncology therapeutics


Fierce Life Sciences and Integral Molecular webinar speakers banner

Register now

Genetic Engineering and Integral Molecular Present – Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array


Thursday, June 22, 2023
Watch the webinar

Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding; however, their predictive value for in vivo safety and toxicity is poor. Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk antibody-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.

In this GEN webinar, our panelists will discuss their experiences using the MPA to rapidly identify potential off-target interactions, resulting in successful IND filings for CAR-T cell therapies where conventional approaches did not suffice. We will also describe the newest additions to this 6,000-protein cell array and the status of its consideration by the FDA as a qualified Drug Development Tool.

With a focus on specificity screening, this webinar assembles experts in antibody discovery and development and features presentations from Integral Molecular, Cabaletta Bio, and The University of Pennsylvania.

  • Understand how Integral Molecular’s MPA is used to identify potential off-target binding liabilities
  • Learn how MPA data supports IND submissions with advantages over traditional tissue cross-reactivity studies
  • Discover how the MPA was used to rapidly evaluate the specificity of novel CAR-T cell therapies for autoimmunity and cancer


GEN and Integral Molecular Webinar- Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array. Headshots of webinar speakers: Rachel Fong of Integral Molecular, Darshil Patel of Cabaletta Bio and Donald Siegel of University of Pennsylvania.